[1]
Muchtar E, Dispenzieri A, Magen H, Grogan M, Mauermann M, McPhail ED, Kurtin PJ, Leung N, Buadi FK, Dingli D, Kumar SK, Gertz MA. Systemic amyloidosis from A (AA) to T (ATTR): a review. Journal of internal medicine. 2021 Mar:289(3):268-292. doi: 10.1111/joim.13169. Epub 2020 Sep 14
[PubMed PMID: 32929754]
[2]
Gertz MA, Dispenzieri A. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA. 2020 Jul 7:324(1):79-89. doi: 10.1001/jama.2020.5493. Epub
[PubMed PMID: 32633805]
Level 1 (high-level) evidence
[3]
Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genetics in medicine : official journal of the American College of Medical Genetics. 2017 Jul:19(7):733-742. doi: 10.1038/gim.2016.200. Epub 2017 Jan 19
[PubMed PMID: 28102864]
[4]
Carvalho A,Rocha A,Lobato L, Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2015 Mar;
[PubMed PMID: 25482846]
[5]
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. The New England journal of medicine. 2018 Sep 13:379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27
[PubMed PMID: 30145929]
[6]
Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, Patterson TA, Riley S, Schwartz JH, Sultan MB, Witteles R. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. European journal of heart failure. 2021 Feb:23(2):277-285. doi: 10.1002/ejhf.2027. Epub 2020 Nov 12
[PubMed PMID: 33070419]
[7]
Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, Boman K, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. JACC. Heart failure. 2021 Feb:9(2):115-123. doi: 10.1016/j.jchf.2020.09.011. Epub 2020 Dec 9
[PubMed PMID: 33309574]
[8]
Said G, Grippon S, Kirkpatrick P. Tafamidis. Nature reviews. Drug discovery. 2012 Mar 1:11(3):185-6. doi: 10.1038/nrd3675. Epub 2012 Mar 1
[PubMed PMID: 22378262]
[9]
Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, Slama MS, Hazenberg BP, Coelho T, European Network for TTR-FAP (ATTReuNET). First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Current opinion in neurology. 2016 Feb:29 Suppl 1(Suppl 1):S14-26. doi: 10.1097/WCO.0000000000000289. Epub
[PubMed PMID: 26734952]
Level 3 (low-level) evidence
[10]
Lamb YN, Deeks ED. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy. Drugs. 2019 Jun:79(8):863-874. doi: 10.1007/s40265-019-01129-6. Epub
[PubMed PMID: 31098895]
[11]
Coelho T,Maia LF,Martins da Silva A,Waddington Cruz M,Planté-Bordeneuve V,Lozeron P,Suhr OB,Campistol JM,Conceição IM,Schmidt HH,Trigo P,Kelly JW,Labaudinière R,Chan J,Packman J,Wilson A,Grogan DR, Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012 Aug 21;
[PubMed PMID: 22843282]
Level 1 (high-level) evidence
[12]
Burton A, Castaño A, Bruno M, Riley S, Schumacher J, Sultan MB, See Tai S, Judge DP, Patel JK, Kelly JW. Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story. Drug design, development and therapy. 2021:15():1225-1243. doi: 10.2147/DDDT.S289772. Epub 2021 Mar 18
[PubMed PMID: 33776421]
[13]
Nawarskas JJ, Shephard EA. Tafamidis: A Novel Treatment for Transthyretin Amyloid Cardiomyopathy. Cardiology in review. 2020 May/Jun:28(3):156-160. doi: 10.1097/CRD.0000000000000306. Epub
[PubMed PMID: 32101907]
[14]
Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, Maurer MS, Planté-Bordeneuve V, Labaudinière R, Mundayat R, Riley S, Lombardo I, Huertas P. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurology and therapy. 2016 Jun:5(1):1-25. doi: 10.1007/s40120-016-0040-x. Epub 2016 Feb 19
[PubMed PMID: 26894299]
[15]
Lockwood PA, Le VH, O'Gorman MT, Patterson TA, Sultan MB, Tankisheva E, Wang Q, Riley S. The Bioequivalence of Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine 4 × 20-mg Capsules in Healthy Volunteers. Clinical pharmacology in drug development. 2020 Oct:9(7):849-854. doi: 10.1002/cpdd.789. Epub 2020 Mar 20
[PubMed PMID: 32196976]
[16]
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3:145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1
[PubMed PMID: 35363499]
Level 1 (high-level) evidence
[17]
Huber P, Flynn A, Sultan MB, Li H, Rill D, Ebede B, Gundapaneni B, Schwartz JH. A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2019 Dec:26(4):203-209. doi: 10.1080/13506129.2019.1643714. Epub 2019 Jul 27
[PubMed PMID: 31353964]
[18]
Ando Y, Sekijima Y, Obayashi K, Yamashita T, Ueda M, Misumi Y, Morita H, Machii K, Ohta M, Takata A, Ikeda S. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study. Journal of the neurological sciences. 2016 Mar 15:362():266-71. doi: 10.1016/j.jns.2016.01.046. Epub 2016 Jan 22
[PubMed PMID: 26944161]
[19]
Klamerus KJ, Watsky E, Moller R, Wang R, Riley S. The effect of tafamidis on the QTc interval in healthy subjects. British journal of clinical pharmacology. 2015 Jun:79(6):918-25. doi: 10.1111/bcp.12561. Epub
[PubMed PMID: 25546001]
[20]
Vervaat FE, Bouwmeester S, Vlaar PJ. Case report regarding the evolution of electrocardiographic and echocardiographic features in cardiac amyloidosis. European heart journal. Case reports. 2021 Jan:5(1):ytaa426. doi: 10.1093/ehjcr/ytaa426. Epub 2021 Jan 11
[PubMed PMID: 33644637]
Level 3 (low-level) evidence
[21]
Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, Rowczenio DM, Gilbertson JA, Hutt DF, Rezk T, Strehina SG, Caringal-Galima J, Manwani R, Sharpley FA, Wechalekar AD, Lachmann HJ, Mahmood S, Sachchithanantham S, Drage EPS, Jenner HD, McDonald R, Bertolli O, Calleja A, Hawkins PN, Gillmore JD. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. 2019 Jul 2:140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169. Epub 2019 May 21
[PubMed PMID: 31109193]
Level 2 (mid-level) evidence
[22]
Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020 Jul 7:142(1):e7-e22. doi: 10.1161/CIR.0000000000000792. Epub 2020 Jun 1
[PubMed PMID: 32476490]
[23]
Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, Grogan M, Kristen AV, Lousada I, Nativi-Nicolau J, Cristina Quarta C, Rapezzi C, Ruberg FL, Witteles R, Merlini G. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation. Heart failure. 2019 Sep:12(9):e006075. doi: 10.1161/CIRCHEARTFAILURE.119.006075. Epub 2019 Sep 4
[PubMed PMID: 31480867]
Level 3 (low-level) evidence
[24]
Masri A, Chen H, Wong C, Fischer KL, Karam C, Gellad WF, Heitner SB. Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History. JAMA cardiology. 2020 Sep 1:5(9):1066-1067. doi: 10.1001/jamacardio.2020.1738. Epub
[PubMed PMID: 32936265]
[25]
Planté-Bordeneuve V, Suhr OB, Maurer MS, White B, Grogan DR, Coelho T. The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Current medical research and opinion. 2013 Jan:29(1):77-84. doi: 10.1185/03007995.2012.754349. Epub 2012 Dec 13
[PubMed PMID: 23193943]
Level 3 (low-level) evidence
[26]
Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017 Apr 4:135(14):1357-1377. doi: 10.1161/CIRCULATIONAHA.116.024438. Epub
[PubMed PMID: 28373528]